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Abstract: Cardiac diseases are the consequence of blockage of blood vessels, scar formation and ultimate loss of 
terminally differentiated cardiomyocytes. Immune cells and oxidative stress easily slow down the cardiac functions 
by manipulating the cardiac tissue matrix. Stem cell-based therapies, especially mesenchymal stem cells (MSCs), 
multipotential nonhematopoietic progenitor cells compensate the cardiac diseases by differentiating into multiple 
lineages of mesenchyme including cardiomyocytes and vascular endothelial cells. Antioxidant and anti-
inflammatory action of MSCs has been explored recently by various research groups. Secretion of biomolecules by 
MSCs perturbs and prevents the initiation, development and the function of the inflammatory cascade. These 
molecules mainly act through Paracrine mode. Anti-inflammatory action of MSCs mediates the cardiac diseases and 
the current progress in elucidating the mechanism and clinical use will be focused in detail in this article. 
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1. Introduction 
 
Millions of people all over the world suffer from 
cardiac diseases and still, the most perfect drug was not 
found out to safely treat the disease. The reasons behind 
the regress of treatment are the minimal symptoms, 
complicate molecular mechanism and risk factors like 
diabetes, smoking, alcoholism, food habits and lack of 
exercise. Unlike earlier mechanisms where 
accumulation of lipid molecules in the arteries causes 
acute cardiac damage, we now understand better the 
mechanisms responsible for the initiation and 
development of cardiac diseases. Recent studies claim 
that inflammation plays a key role in developing 
atherosclerosis, myocardial infarction (MI), 
endocarditis, inner layer of the heart, especially heart 
values, myocarditis, inflammation of the muscular part 
of the heart (Lippy et al., 2002). Inflammation leads the 
progression of complex plaque from fatty streaks. As 
the plaque evolves, T cells activate macrophages by 
either cyto-signaling or contact through CD40 ligation 
to secrete panoply of molecules, including cytokines 
and matrix metalloproteases that make up the collagen 
that forms the fibrous cap, which ordinarily protects the 
plaque. As a result, the fibrous cap becomes thin and 
friable and can rupture, thus creating a thrombus that 
can lead to MI or other complications.  
MSCs was first characterized by Friedenstein and 
colleagues, who identified an adherent fibroblast-like 
population in the adult bone marrow that could 
regenerate rudiments of, bone in vivo [Friedenstein et 
al., 1968; Friedenstein 1976; Friedenstein et al., 1987; 
Owen and Friedenstein, 1988]. Since then, MSCs has 
been isolated from many other tissues including 
adipose, cord blood, fetal liver, blood, bone marrow and 
lung [Erices et al., 2000; Campagnoli et al., 2001; 
Noort et al., 2002]. Furthermore, MSCs display genetic 
stability reproducible characteristics in widely 
dispersed laboratories and compatibility with tissue 
engineering principles [Pittinger et al., 1993; Lodie et 
al., 2002; Gronthos et al., 2003 (6–8)]. Gene therapy, 
growth factor application, and tissue engineering in 
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combination with stem cell transplantation are thought 
to improve the effectiveness of stem cells. However, the 
specific mechanism remains controversy followed by 
stem cell transplantation. The current data on the anti-
inflammatory actions and mechanisms of MSCs should 
be discussed in a narrowed manner to display the dearth 
of studies and to explore and intensify for the 
application of MSCs for the treatment of cardiac 
diseases. 
 
2. Cardiogenesis from MSC 
 
Myocardium tissue has limited intrinsic 
regenerative capacity because of its terminally 
differentiated cardiomyocytes and once it is affected, 
the soft myocardium is typically replaced with 
noncontractile scar tissue, often initiating congestive 
heart failure. Heart failure ensues when contractile 
reserve is depleted below a critical threshold. In many 
instances, the only effective therapy for end-stage 
ischemic heart disease is cardiac transplantation. 
Unfortunately, the number of available donor hearts is 
well below that of recipients. Stem cell therapies offer 
tremendous possibilities for curative approaches toward 
restoring lost myocardium and cardiac function through 
multiple strategies. As one of the least regenerative 
organs in the body, the heart would greatly benefit by 
the regenerative therapy. MI results in large-scale loss 
of myocardial muscle. Where, other cardiac diseases 
such as hypertension, valve disease and genetic disorder 
cause sporadic lose of myocytes. 
Differentiation of MSCs into cardiomyocytes 
followed by improvement in myocardial performance 
attracted many investigators [Orlic et al., 2001; Jackson 
et al., 2002; Yoon et al., 2005]. Various sources of stem 
cells have been explored to differentiate into 
cardiomyocytes. To identify a source of stem cells 
capable of restoring damaged cardiac tissue, highly 
enriched hematopoietic stem cells the so-called side 
population (SP) cells, were transplanted into lethally 
irradiated mice subsequently rendered ischemic by 
coronary artery occlusion for 60 minutes followed by 
reperfusion. The SP cells (CD34–/low, c-Kit+, Sca-1+) 
or their progeny migrated into ischemic cardiac muscle 
and blood vessels, differentiated to cardiomyocytes and 
endothelial cells and contributed to the formation of 
functional tissue. Donor-derived cardiomyocytes were 
found primarily in the peri-infarct region at a 
prevalence of around 0.02 % and were identified by 
expression of lacZ and α-actinin and lack of expression 
of CD45. Donor-derived endothelial cells were 
identified by expression of lacZ and Flt-1, an 
endothelial marker shown to be absent on SP cells. In 
another study, CD133+ cells were transplanted into 
ischemic heart (Rafii and Lyden, 2003). CD133+ cells 
integrated into sites of neovascularization and 
differentiated into mature endothelial cells. Less than 
1% of nucleated BMCs are CD133+ positive and 
however, this source is limited because only limited 
numbers of CD133+ cells can be obtained for 
therapeutic purposes and cannot be easily expanded in 
vivo. The presence of resident cardiac stem cell (CSC) 
population(s) capable of differentiating into 
cardiomyocyte or Vascular lineages suggests that these 
cells could be used for cardiac tissue repair (Beltrami et 
al., 2003; Oh et al., 2003). It has been reported that 
intramyocardial injection of these cells after AMI in 
mice promotes cardiomyocyte and vascular cell 
formation and leads to an improvement in systolic 
function (Messina et al., 2004). However, invasion for 
biopsy is tedious and cannot be forwarded easily in 
clinical level. 
To improve the potential of stem cells towards 
vascularization, angiogenesis and myocytes 
regeneration, stem cells were genetically modified 
using various genes. MSCs were transfected with the 
VEGF gene responsible for angiogenesis (Cao et al., 
2007) and increased angiogenesis was found out. To 
reduce cell loss after transplantation Song et al., (2005) 
introduced the fibroblast growth factor-2 (FGF-2) gene 
ex vivo before transplantation. Viable cells persisted 4 
weeks after implantation of 5.0*105 FGF-2-MSCs into 
infarcted myocardia. Expression of cardiac troponin T 
and a voltage-gated Ca2+ channel (CaV2.1) increased 
and new blood vessels formed. These studies suggested 
that genetic modification of MSCs before 
transplantation could be useful for treating cardiac 
diseases and end-stage cardiac failure. 
 
3. Antioxidant and Anti-Apoptotic Effects 
 
Oxidative stress and immune cells are the major 
backbone in the reperfusion and ischemia injury 
(Kaminski et al., 2002). It could easily be predicted the 
role of oxidants and simultaneous activation of the 
inflammatory cascade in the development of cardiac 
diseases. Many pharmacological drugs have been 
approved to reduce the levels of antioxidants and 
subsequent nullification of cardiac diseases (Nuttall et 
al., 1999). However, each has owned its disadvantages 
and especially they target single molecules or pathway. 
Stem cells from various sources are used to repair the 
MI and Cardiovascular diseases (CVD) etc. Stem cells 
can not only regenerate the diseased organs but also can 
cure the diseases by multiple therapeutic strategies. One 
of the earliest and most striking examples was provided 
by Mangi et al., (2003) who predicted that 
overexpression of the anti-apoptotic signaling protein 
Akt in MSCs would improve myocardial repair 
following AMI through pro-survival effects. As shown 
in this and subsequent studies, Akt overexpression by 
retroviral transduction of MSCs was associated with 
significantly reduced infarct size and myocardial 
remodeling and improved left ventricular function. In 
another study to improve the MI, MSCs was subjected 
to genetic engineering with plasmid causing secretion 
Antioxidant & Anti-Inflammatory Action of Stem Cells in Cardiac Diseases                Pulavendran et al 
 
J. Adv. Lab. Res. Biol.                                                                                                                                                                                                                                             73 
of anti-apoptotic and angiogenic peptide. Spermine 
introduced dextran of cationized polysaccharide 
(spermine-dextran) a non-viral vector was internalized 
into MSCs by way of a sugar-recognizable receptor to 
enhance the expression level of plasmid 
deoxyribonucleic acid (DNA). When genetically 
engineered by the spermine-dextran complex with 
plasmid DNA of adrenomedullin (AM). MSCs secreted 
a large amount of AM an anti-apoptotic and angiogenic 
peptide. Transplantation of AM gene engineered MSCs 
improved cardiac function after myocardial infarction 
significantly more than MSCs alone (Jo et al., 2007). 
Chen et al., (2008) examined the changes of 
oxidative stress levels and mitochondria in over 
confluence culture-induced replicative senescence of 
MSCs. The results showed that human umbilical cord 
blood-derived MSCs (HUMSCs) and bone marrow-
derived MSCs (BMSCs) reached replicative senescence 
at the 40th and 38th population doublings respectively. 
Viability assay showed that HUMSCs were more 
resistant to exogenous ROS than BMSCs. This study 
showed the antioxidant properties of the primarily 
isolated MSCs as well as few passaged cells. However, 
over the period of repeated culture, the antioxidant 
properties of stem cells decrease. Tang et al., (2005) 
proved that hypoxia-regulated heme oxygenase-1 (HO-
1) plasmid modification of MSCs enhanced the 
tolerance of engrafted MSCs to hypoxia-reoxygenation 
injury in vitro and improves their viability in ischemic 
hearts. 
Circulating progenitor cells with an endothelial 
phenotype (EPCs) can be isolated from peripheral 
blood and contribute to neovascularization and 
endothelial regeneration. Whether EPCs are equipped 
with an antioxidative defense or to provide resistance 
against oxidative stress were evaluated. EPCs exhibited 
a significantly lower basal reactive oxygen species 
(ROS) concentration as compared with mature human 
umbilical vein endothelial cells (HUVECs). Consistent 
expression of the intracellular antioxidative enzymes 
such as catalase, glutathione peroxidase and manganese 
superoxide dismutase (MnSOD) was significantly 
higher in EPCs compared to HUVECs. Altogether it 
was concluded that EPCs have the potential to secrete 
antioxidative enzymes and thereby to protect against 
oxidative stress consistent with their progenitor cell 
character (Dembach et al., 2004). Tolerance of 
oxidative stress of human endothelial progenitor cells 
(EPCs) due to the intrinsically high expression of 
manganese superoxide dismutase was also reported (He 
et al., 2004). 
Few reports have shown that muscle-derived Stem 
cells (MDSCs) have lower rates of stress-induced cell 
death, and it was speculated that the MDSCs’ increased 
regenerative capacity which may relate to an increased 
resistance to oxidative and inflammatory stress (Oshima 
et al., 2005; Deasy et al., 2007). Evidence of increased 
enzymatic and nonenzymatic antioxidant capacity of 
MDSCs was observed in terms of higher levels of 
superoxide dismutase and glutathione which appeared 
to confer a differentiation and survival advantage. In 
addition, when glutathione levels of the MDSCs are 
lowered to that of myoblasts, the transplantation 
advantage of MDSCs over myoblasts was lost when 
transplanted into both skeletal and cardiac muscles. 
These findings elucidated an important cause for the 
superior regenerative capacity of MDSCs and provided 
functional evidence for the emerging role of antioxidant 
capacity as a critical property for MDSCs survival post-
transplantation (Urish et al., 2009). Later, increase in 
the proliferation of induced pluripotent stem cells was 
reported followed by the treatment of vitamin C 
(Esteban et al., 2010). 
As the age progresses, the number of MSCs and 
their regenerative potential decreases (Raucher et al., 
2003). Antioxidants also decrease during the aging 
process which causes muscular cell damage (Presant et 
al., 2007). Aging of stem and progenitor cells was 
suggested to account for aging of tissue and whole 
organisms (Sharpless and Depinho, 2007). In principle, 
MSCs from aged individuals may be altered in quality 
or quantity (for details see the review: Sethe et al., 
2006). It was demonstrated not only that MSCs 
concentration in bone marrow declines with age but 
also that their function is altered, especially their 
migratory capacity and susceptibility toward 
senescence. A functional annotation clustering study 
revealed that age-affected molecular functions were 
associated with cytoskeleton organization and 
antioxidant defense. These proteome screening results 
were supported by lower actin turnover and diminished 
antioxidant power in aged MSCs respectively. The 
reasons for the compromised cellular function of aged 
MSCs were postulated that: 
a) Declined responsiveness to biological and 
mechanical signals due to a less dynamic actin 
cytoskeleton and 
b) Increased oxidative stress exposure favoring 
macromolecular damage and senescence. 
That implied that MSC-based therapeutic 
approaches for the elderly should focus on attracting the 
cells to the site of injury and oxidative stress protection 
rather than merely stimulating differentiation (Kasper et 
al., 2009). Thus, the results of these studies confirm the 
treatment effect of MSCs by antioxidant as well as anti-
apoptotic effects in addition to the differentiation 
potential. 
 
4. Anti-Inflammatory Effects 
 
Immune cells or proinflammatory cytokine IFNy 
alone or together with TNFα, IL-1α or IL-1β should 
activate the MSC for the initiation of 
immunosuppression properties (Krampera et al., 2006; 
Ren et al., 2008). The necessity of this activation has 
also been proved in vivo in a model of graft versus host 
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disease (GVHD) since recipients of IFNγ–/– T cells did 
not respond to MSC treatment and succumbed to 
GVHD (Polichert et al., 2008). Indeed, MSCs from 
mice deficient for the IFNγ receptor 1 do not have 
immunosuppressive activity, highlighting the important 
role of IFNγ in this process (Ren et al., 2008). Although 
target cell–MSC interactions may play a role, the MSC-
mediated immunosuppression mainly acts through the 
secretion of soluble molecules that are induced or 
upregulated following cross-talk with target cells. 
Induction of inducible nitric-oxide synthase (iNOS) 
by murine MSCs and the production of nitric oxide 
were suggested to play a major role in T-cell 
proliferation inhibition (Sato et al., 2007). The 
expression level of iNOS mRNA in human MSCs was 
minimal (Ren et al., 14) and the secretion of nitric 
oxide by human MSCs was undetectable. Indeed, 
different mechanisms of immunosuppression exist in 
different species since human MSCs employ 
indoleamine 2,3-dioxygenase (IDO) as a major effector 
molecule whereas nitric oxide plays a critical role in 
mouse MSCs (Ren et al., 2008). One of the first in vivo 
studies showed that systemic infusion of MSCs isolated 
from bone marrow prolonged the survival of allogeneic 
skin grafts from 7 to 11 days in baboons receiving 
MSCs (Bartholomew et al., 2001). Although 
regeneration via MSC differentiation into 
cardiomyocytes was initially considered, further studies 
demonstrated that the predominant beneficial 
mechanism was through enhanced production of anti-
inflammatory, pro-repair factors (Noiseux et al., 2006). 
MSC-Akt decreased infarct size at 3 days and restored 
early cardiac function. In conclusion, MSC-Akt 
improved early repair despite transient engraftment, 
low levels of cellular fusion and differentiation. These 
new observations further confirmed the recently 
reported data by the same group that early paracrine 
mechanisms mediated by MSC are responsible for 
enhancing the survival of existing myocytes and that 
Akt could alter the secretion of various cytokines and 
growth factors (Noiseux et al., 2006). 
MSCs secret number of molecules which play 
different kinds of activities during the pathological 
conditions since it is difficult to explain the timing and 
extent of improvement by only the effect through 
cardiac regeneration or cell fusion from MSCs. The 
repair function of MSCs is also involved with the 
secretion of paracrine factors, which can help to prevent 
apoptosis, promote angiogenesis, assist in matrix 
reorganization and augment circulating MSCs 
recruitment (Caplan et al., 2006). Transplanted MSCs 
could upregulate multiple growth factors such as 
vascular endothelial growth factor [angiogenic, increase 
blood flow and decrease apoptosis (Tang et al., 2005)], 
fibroblast growth factor [angiogenic, antifibrotic and 
anti-apoptotic factors (Ono et al., 2004)], hepatocyte 
growth factor [not only angiogenic but also 
cardioprotective, including anti-apoptotic, mitogenic 
and antifibrotic activities (Nakamura et al., 2000)], 
adrenomedullin [angiogenic, anti-apoptotic and 
antifibrotic activities (Okumura et al., 2004; Tsuruda et 
al., 1999; Yoshihara et al., 2003)], and insulin-like 
growth factor-1 [enhancing myocardial growth, anti-
apoptotic and positive inotropic effects (Fuller et al., 
1992; Florinie et al., 1996)]. The use of cytokine-
mobilized autologous MSCs for infarcted myocardium 
(alone or in conjunction with currently used therapies) 
has the potential to significantly reduce morbidity and 
mortality associated with cardiac remodeling. If 
paracrine factors are the key agents, isolating and 
delivering such factors at high concentrations or 
engineering MSCs to secrete larger amounts could 
result in more significant protection. 
Among these factors, indoleamine 2,3-dioxygenase 
(IDO) has consistently been reported (Meisel et al., 
2004; Maby et al., 2009). On stimulation with IFNγ, 
this enzyme metabolizes tryptophan to kynurenine, 
causing depletion of local tryptophan and accumulation 
of toxic breakdown products. IDO however, exerts its 
effects mainly through the local accumulation of 
tryptophan metabolites rather than through tryptophan 
depletion (Ryan et al., 2007). Whereas the majority of 
studies indicate a potentially important function for the 
IDO, human MSCs lacks both IFNγ receptor 1 and IDO 
still exerted important immunomodulatory activity 
(Gieseke et al., 2007). This observation may be 
explained at least in part by a recent study reporting that 
Toll-like receptors expressed on MSCs augment their 
immunosuppressive activity in the absence of IFNγ 
through an autocrine IFNβ signaling loop, which was 
dependent on protein kinase R and able to induce IDO 
(Opitz et al., 2009). Contrary to human MSCs, lack of 
IDO activity was constantly reported for murine MSCs 
(Djouad et al., 2007; Ren et al., 2009). 
Akt overexpression in MSCs of tumor necrosis 
factor receptor (TNFR) via AAV was associated with 
reduced cardiac inflammation and Apoptosis and 
improved LV function in rat AMI (Bao et al., 2008). 
Prostaglandin E2 (PGE2) has also been involved in 
the immunosuppressive activity of MSCs. PGE2 is a 
product of arachidonic acid metabolism that acts as a 
powerful immune suppressant, inhibiting T-cell 
mitogenesis and IL-2 production and is a cofactor for 
the induction of T-helper type 2 lymphocyte activities. 
Production of PGE2 by MSCs is enhanced following 
TNFα or IFNγ stimulation and its inhibition using 
specific inhibitors resulted in restoration of T-
lymphocyte proliferation (Aggarwal and Pittinger, 
2005). MSC-derived PGE2 was shown to act on 
macrophages by stimulating the production of IL-10 
and on monocytes by blocking their differentiation 
toward dendritic cells (DCs) (Nemeth et al., 2009; 
Spaggian et al., 2009). IL-6 secreted by MSC was 
reported to be involved in the inhibition of monocyte 
differentiation toward DCs, decreasing their stimulation 
ability on T cells (Jiang et al., 2005). Bone marrow 
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MSCs improved function by attenuating post-MI 
inflammation and repair. 
Inflammatory cytokines and cells were measured 
and their impacts on the (myo) fibroblastic repair 
response, angiogenesis, and scar formation were 
determined. BMC implantation reduced the decline in 
fractional shortening and ventricular dilation. 
Interestingly, BMC implantation caused a 1.6-fold 
increase in the number of macrophages infiltrating the 
infarct but did not affect neutrophils. This increase was 
associated with a 1.9-fold higher myocardial TNF-α 
level. The heightened inflammatory response was 
associated with a 1.4-fold induction of transforming 
growth factor-β and a 1.3-fold induction of basic FGF. 
These changes resulted in a 1.6-fold increase in α-
smooth muscle actin and a 1.9-fold increase in total 
discoidin domain receptor 2-expressing cells in the 
BMC group. Consistent with a more robust repair-
mediated scar contracture the final scar size was 0.7-
fold smaller in the BMC group. In conclusion, after 
myocardial infarction, BMC therapy induced a more 
robust inflammatory response that improved the 
priming of the (myo) fibroblast repair phase (Sun et al., 
2009). 
 
5. Conclusion 
 
Molecular understanding displayed a different 
perspective of cardiac diseases as a result of 
inflammatory events rather than lipid storage problem. 
Our assessment and management of cardiovascular 
disease risk must evolve in step with a deepened 
understanding of pathophysiologic mechanisms. 
Lifestyle modification and proven medical therapies 
must join stenting and coronary bypass surgery. 
Chronological data indicate that MSCs represents a 
promising alternative strategy not only for the 
cardiomyocytes regeneration but also in the 
immunomodulation of cardiac diseases. However 
number of studies published on the viability of MSC for 
cardiac repair through preclinical and clinical tests, 
bench to bed still remains scarce. Transfer of MSCs 
into clinical formulation depends upon the mode of 
injection, number and times of injection, techniques to 
retain cells at the injured areas to furnish autocrine and 
paracrine effects. Genetic engineering of MSC with the 
factors that will augment the secretion of soluble factors 
should be explored while maintaining the regenerative 
potential to completely utilize the potential of 
multipotent MSCs. 
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